Subsidy to beef-up store security
Following the recent spate of ram-raids, dispensing optician outlets could be eligible for a NZ$4,000 government subsidy towards fog-machine installation. Designed to disorientate criminals and
1 min read
SR
Staff reporters
4295 articles
Retinal cells’ glucose defence
New research has found that retinal endothelial cells can self-protect against the damaging effects of hyperglycaemia (HG) in diabetic patients.
1 min read
Monkeypox alert for ECPs
US ophthalmologists have urged eyecare professionals (ECPs) to be vigilant in spotting symptoms of monkeypox-related ophthalmic disease (MPXROD), which may be associated with severe ocular and visual
1 min read
Doxycycline for lower IOP?
A US pilot study has shown that low-dose doxycycline, an antibiotic with anti-inflammatory characteristics used to treat bacterial infections, meibomian gland dysfunction and rosacea, may be a useful adjunct therapy for intraocular pressure (IOP) reduction.
2 min read
Promotions recognise academic success
The University of Auckland has appointed two new associate professors: Dr James McKelvie, senior lecturer with the Department of Ophthalmology, and Dr Julie Lim, senior lecturer with the department of medical science and senior research fellow with the department of physiology.
2 min read
CRVO: 3-year anti-VEGF outcomes
A study arising from the University of Sydney’s Fight Retinal Blindness! registry has concluded patients with central retinal vein occlusion (CRVO) who commenced VEGF inhibitors in routine care, and for whom follow-up was available, had visual acuity (VA) improvements of around 12 letters at three y
2 min read
WM’s sustainability move
William Morris London is introducing a new socially responsible range of eyewear, supporting its drive to improve traditional manufacturing processes to help the climate and the planet.
1 min read
Fundamental change for NZ clinical trials
A report by Aotearoa’s lead health agencies has recommended system-level changes to maximise the benefits of clinical trials to strengthen research culture and attract funding, all with an emphasis on better ethnic representation to improve the nation’s healthcare equity.
3 min read
IRD gene therapy advances
On the heels of Luxturna’s (voretigene neparvovec-rzyl) Medsafe approval in New Zealand to treat RPE65-mediated Leber congenital amaurosis (LCA), several other gene therapies for inherited retinal diseases (IRDs) are on the horizon.
2 min read
Urgent recall of consumer eyedrops
Following a death, five cases of vision loss, and hospitalisations, the US Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA) have warned consumers and
1 min read
Anti-keratitis device unveiled in UK
An award-winning, New Zealand-designed handheld device to destroy keratitis-causing microbes within 10 seconds is nearing commercial use in animals, which should help speed human commercialisation and perhaps one day provide a compelling alternative to antibiotics.
3 min read
Aflibercept’s superior tapering
A retrospective analysis of a wet age-related macular degeneration (AMD) study found nearly half of patients treated with aflibercept could safely stop treatment after one year without further vision loss, versus 17% of patients receiving bevacizumab injections.
1 min read